315 related articles for article (PubMed ID: 29282679)
1. The Preventive Intervention of Hereditary Breast Cancer.
Cao A; Huang L; Shao Z
Adv Exp Med Biol; 2017; 1026():41-57. PubMed ID: 29282679
[TBL] [Abstract][Full Text] [Related]
2. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
3. Management updates for women with a BRCA1 or BRCA2 mutation.
Nusbaum R; Isaacs C
Mol Diagn Ther; 2007; 11(3):133-44. PubMed ID: 17570734
[TBL] [Abstract][Full Text] [Related]
4. [Problems raised by the gynaecologic management of women with BRCA 1 & 2 mutations.Gynécol Obstét Fertil 2003;31:370-377].
Stoppa-Lyonnet D
Gynecol Obstet Fertil; 2003 Oct; 31(10):888-9; author reply 889. PubMed ID: 14642951
[No Abstract] [Full Text] [Related]
5. [Prophylactic mastectomy in women at high risk for breast cancer: indications and options].
Scheufler O; Fritschen Uv
Handchir Mikrochir Plast Chir; 2008 Aug; 40(4):239-47. PubMed ID: 18716986
[TBL] [Abstract][Full Text] [Related]
6. Risk management options elected by women after testing positive for a BRCA mutation.
Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB
Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485
[TBL] [Abstract][Full Text] [Related]
7. Preventive surgery is associated with reduced cancer risk and mortality in women with BRCA1 and BRCA2 mutations.
Domchek SM; Rebbeck TR
LDI Issue Brief; 2010; 16(2):1-4. PubMed ID: 21545057
[TBL] [Abstract][Full Text] [Related]
8. Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.
Hirasawa A; Masuda K; Akahane T; Tsuruta T; Banno K; Makita K; Susumu N; Jinno H; Kitagawa Y; Sugano K; Kosaki K; Aoki D
Jpn J Clin Oncol; 2013 May; 43(5):515-9. PubMed ID: 23487443
[TBL] [Abstract][Full Text] [Related]
9. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
[TBL] [Abstract][Full Text] [Related]
10. Hereditary breast and ovarian cancer: review and future perspectives.
Lux MP; Fasching PA; Beckmann MW
J Mol Med (Berl); 2006 Jan; 84(1):16-28. PubMed ID: 16283147
[TBL] [Abstract][Full Text] [Related]
11. Reducing breast cancer incidence in familial breast cancer: overlooking the present panorama.
Marchetti P; Di Rocco CZ; Ricevuto E; Bisegna R; Cianci G; Calista F; Sidoni T; Porzio G; Ficorella C
Ann Oncol; 2004; 15 Suppl 1():I27-I34. PubMed ID: 15280184
[TBL] [Abstract][Full Text] [Related]
12. [Methods of surgical prevention of breast cancer and of ovarian cancer in BRCA mutation carriers].
Bit-Sava EM; Belogurova MB; Imianitov EN; Balandov SG; Korniushin OV; Borisov MK
Vopr Onkol; 2013; 59(2):5-11. PubMed ID: 23814843
[No Abstract] [Full Text] [Related]
13. Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic.
Heemskerk-Gerritsen BA; Brekelmans CT; Menke-Pluymers MB; van Geel AN; Tilanus-Linthorst MM; Bartels CC; Tan M; Meijers-Heijboer HE; Klijn JG; Seynaeve C
Ann Surg Oncol; 2007 Dec; 14(12):3335-44. PubMed ID: 17541692
[TBL] [Abstract][Full Text] [Related]
14. BRCA mutation genetic testing implications in the United States.
Bayraktar S; Arun B
Breast; 2017 Feb; 31():224-232. PubMed ID: 27931006
[TBL] [Abstract][Full Text] [Related]
15. The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy.
Giannakeas V; Narod SA
Breast Cancer Res Treat; 2018 Jan; 167(1):263-267. PubMed ID: 28914396
[TBL] [Abstract][Full Text] [Related]
16. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
[TBL] [Abstract][Full Text] [Related]
17. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome.
Roukos DH; Briasoulis E
Nat Clin Pract Oncol; 2007 Oct; 4(10):578-90. PubMed ID: 17898808
[TBL] [Abstract][Full Text] [Related]
18. Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Familial Breast Cancer Collaborative Group.
Vasen HF; Haites NE; Evans DG; Steel CM; Møller P; Hodgson S; Eccles D; Morrison P; Stoppa Lyonet D; Chang-Claude J; Caligo M
Eur J Cancer; 1998 Nov; 34(12):1922-6. PubMed ID: 10023316
[TBL] [Abstract][Full Text] [Related]
19. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
20. Choice of management of southern Chinese BRCA mutation carriers.
Kwong A; Wong CH; Shea C; Suen DT; Choi CL
World J Surg; 2010 Jul; 34(7):1416-26. PubMed ID: 20182723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]